연구성과로 돌아가기
2023 연구성과 (147 / 285)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study | Purpose This study aimed to report the final analysis of time-on-treatment (TOT) and overall survival (OS) in patients with advanced -stage epidermal growth factor receptor (EGFR)+ non-small cell lung cancer (NSCLC) who received sequential afatinib and osimertinib and to compare the outcomes with other second-line regimens (comparator group).Materials and Methods In this updated report, the existing medical records were reviewed and rechecked. TOT and OS were updated and analyzed according to clinical features using the Kaplan-Meier method and log-rank test. TOT and OS were compared with those of the comparator group, in which most patients received pemetrexed-based treatments. A multivariable Cox proportional hazard model was used to evaluate features that could affect survival outcomes.Results The median observation time was 31.0 months. The follow-up period was extended to 20 months. A total of 401 patients who received first-line afatinib were analyzed (166 with T790M+ and second-line osimertinib, and 235 with unproven T790M and other second-line agents). Median TOTs on afatinib and osimertinib were 15.0 months (95% confidence interval [CI], 14.0 to 16.1) and 11.9 months (95% CI, 8.9 to 14.6), respectively. The median OS in the osimertinib group was 54.3 months (95% CI, 46.7 to 61.9), much longer than that in the comparator group. In patients who received osimertinib, the OS was longest with Del19+ (median, 59.1; 95% CI, 48.7 to 69.5).Conclusion This is one of the largest real-world studies reporting the encouraging activity of sequential afatinib and osimertinib in Asian patients with EGFR+ NSCLC who acquired the T790M mutation, particularly Del19+. | Kim, Taeyun; Jang, Tae Won; Choi, Chang Min; Kim, Mi-Hyun; Lee, Sung Yong; Chang, Yoon Soo; Lee, Kye Young; Kim, Seung Joon; Yang, Sei Hoon; Ryu, Jeong Seon; Lee, Jeong Eun; Lee, Shin Yup; Park, Chan Kwon; Lee, Sang Hoon; Jang, Seung Hun; Yoon, Seong Hoon; Oh, Hyung-Joo | Kosin Univ, Kosin Univ Gospel Hosp, Dept Internal Med, Coll Med, 262 Gamcheon Ro, Busan 49267, South Korea; Samsung Med Ctr, Dept Internal Med, Seoul, South Korea; Kosin Univ, Coll Med, Gospel Hosp, Dept Internal Med, Busan, South Korea; Univ Ulsan, Asan Med Ctr, Coll Med, Dept Internal Med, Seoul, South Korea; Pusan Natl Univ, Dept Internal Med, Sch Med, Pusan Natl Univ Hosp, Busan, South Korea; Biomed Res Inst, Busan, South Korea; Korea Univ, Guro Hosp, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med, Seoul, South Korea; Yonsei Univ, Gangnam Severance Hosp, Dept Internal Med, Seoul, South Korea; Konkuk Univ, Med Ctr, Dept Internal Med, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea; Wonkwang Univ Hosp, Dept Internal Med, Iksan, South Korea; Inha Univ Hosp, Dept Internal Med, Incheon, South Korea; Chungnam Natl Univ Hosp, Dept Internal Med, Daejeon, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Internal Med, Seoul, South Korea; Yonsei Univ, Coll Med, Severance Hosp, Dept Internal Med, Seoul, South Korea; Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Anyang, South Korea; Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Yangsan, South Korea; Chonnam Natl Univ, Hwasun Hosp, Dept Internal Med, Hwasun, South Korea | ; Kim, Woo/A-8216-2019; Lee, Joo Yong/ADE-2110-2022; Kim, Taeyun/AAL-3477-2021; Lee, Jeong Eun/R-8689-2019; Lee, Sang-Hoon/ABH-6210-2020 | 57213164256; 7102426031; 14024046800; 26323727500; 56734650000; 58293916800; 8720534800; 57225930594; 7406950928; 7401868634; 57209104622; 49863712700; 14623269200; 57207065392; 7402219050; 55479240500; 57216363864 | jangtw22@hanmail.net; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 4 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 1.21 | 2025-06-25 | 6 | 8 | Afatinib; Osimertinib; Real-world effectiveness; Non-small-cell lung carcinoma; ErbB receptors | ACQUIRED T790M; ASIAN PATIENTS; MUTATION; TRENDS; SURVIVAL | Afatinib; ErbB receptors; Non–small-cell lung carcinoma; Osimertinib; Real-world effectiveness | Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; afatinib; epidermal growth factor receptor; osimertinib; pemetrexed; afatinib; EGFR protein, human; epidermal growth factor receptor; osimertinib; protein kinase inhibitor; adrenal metastasis; adult; advanced cancer; aged; Article; bone metastasis; brain metastasis; cancer staging; clinical feature; clinical outcome; controlled study; ECOG Performance Status; female; follow up; heart metastasis; human; Kaplan Meier method; liver metastasis; lung metastasis; major clinical study; male; non small cell lung cancer; observational study; overall survival; patient coding; pleura metastasis; retrospective study; South Korea; time to treatment; treatment outcome; genetics; lung tumor; mutation | English | 2023 | 2023-10 | 10.4143/crt.2023.493 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | In silico and docking studies on the binding activities of Keap1 of antioxidant compounds in non-oilseed legumes | We used in silico methods to predict the physiochemical and pharmacological characteristics, toxicity, and biological activities of the screened compounds. All compounds showed positive results while calculating their physiochemical and pharmacokinetic descriptors. Using the Prediction of Activity Spectra for Substances (PASS) software on compounds form non-oilseed legumes, we identified compounds (mainly 4 polyphenol compounds) with anti-infective, anti-eczematic, antimutagenic, muco-membranous protector, fibrinolytic, anticarcinogenic, hepato-protectant, cardioprotectant, antioxidant, and astringent effect. PASS predicted HO-1 expression enhancing and free radical scavenging properties for gallic acid, coumaric acid, catechin, and epicatechin. Data about validation protocols for molecular docking of ligand IVV to Keap1 was performed by root mean square deviation (RMSD) value is used to validate docking protocol and representation mainly for analyzing stability of protein and predicting conformational changes of protein. Molecular docking is a powerful technique for studies of receptor-ligand interaction and has led to the discovery of Keap1-Nrf2 small molecule inhibitors. Keap1 inhibits the degradation of Nrf2. Our results suggest that screened compounds from non-oilseed legumes can effectively interact with the Keap1 binding site and dissociate Keap1 and Nrf2. The screened compounds from non-oilseed legumes that displayed high binding affinities with Keap1 are promising new Nrf2 activators. We performed molecular docking to identify the molecular interactions of gallic acid, catechin, and epicatechin with Keap1. Non | Diniyah, Nurud; Alam, Md Badrul; Javed, Ahsan; Alshammari, Fanar Hamad; Choi, Hee-Jeong; Lee, Sang -Han | Kyungpook Natl Univ, Grad Sch, Dept Food Sci & Biotechnol, Daegu 41566, South Korea; Univ Jember, Fac Agr Technol, Jember 68121, East Java, Indonesia; Kyungpook Natl Univ, Food & Bioind Res Inst, Inner Beauty Antiaging Ctr, Daegu 41566, South Korea | ftp, nurud/AAU-1190-2020; Javed, Ahsan/ABK-2648-2022; Lee, Seung Eun/ABG-1607-2021; Alam, Md Badrul/AAK-7176-2021 | 57201987396; 56706777100; 57204433098; 57191860948; 57201125608; 57221453703 | sang@knu.ac.kr; | ARABIAN JOURNAL OF CHEMISTRY | ARAB J CHEM | 1878-5352 | 1878-5379 | 16 | 1 | SCIE | CHEMISTRY, MULTIDISCIPLINARY | 2023 | 5.3 | 28.4 | 1.14 | 2025-06-25 | 7 | 12 | In silico; Keap1; Molecular docking; Nrf2; Non-oilseed legumes | DRUG SOLUBILITY; PREDICTION; DESIGN | In silico; Keap1; Molecular docking; Non-oilseed legumes; Nrf2 | Antioxidants; Binding energy; Flavonoids; Forecasting; Free radicals; Ligands; Molecular modeling; Phenols; Plants (botany); Proteins; Epicatechin; Gallic acids; In-silico; Keap1; Molecular docking; Non-oilseed legume; Nrf2; Physio-chemical; Silico studies; Spectra's; Oilseeds | English | 2023 | 2023-01 | 10.1016/j.arabjc.2022.104414 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Novel Cu(ii) complexes as DNA-destabilizing agents and their DNA nuclease activity | Here, we report a series of four novel Cu complexes, namely 2-(piperidin-1-ylmethyl)quinoline copper(II) nitrate, [LACu(NO3)(2)] (Cu1), 4-(quinolin-2-ylmethyl)morpholine copper(II) nitrate, [LBCu(NO3)(2)] (Cu2), 4-(quinolin-2-ylmethyl)morpholine copper(II) chloride, [LBCuCl2] (Cu3), and 2-(piperidin-1-ylmethyl)pyridine copper(II) chloride, [LCCu(mu-Cl)Cl](2) (Cu4). X-ray diffraction studies revealed that the geometry around the Cu(II) center could be best described as distorted octahedral in Cu1 and Cu2, whereas Cu3 and Cu4 showed distorted tetrahedral and square pyramidal geometries, respectively. DNA binding studies showed that Cu complexes Cu1-3 containing quinoline interacted via minor groove binding, whereas the Cu4 complex containing pyridine interacted via intercalation. All Cu complexes containing quinoline and pyridine caused destabilization of DNA at specific homogeneous G-C regions. The Cu1-3 complexes as groove binders destabilized the DNA structure much more than the Cu4 complex as an intercalator. Regarding groove binders, the Cu2 complex containing quinoline and morpholine caused the highest distortion and destabilization of the DNA structure, leading to high DNA cleavage efficiency. | Kwon, Hee Chang; Lee, Da Hyun; Yoon, Minyoung; Nayab, Saira; Lee, Hyosun; Han, Ji Hoon | Andong Natl Univ, Dept Chem & Biol Engn, 1375 Gyeongdong Ro, Andong 36729, Gyeongbuk, South Korea; Kyungpook Natl Univ, Dept Chem, 80 Daehakro, Daegu 41566, South Korea; Kyungpook Natl Univ, Green Nano Mat Res Ctr, 80 Daehakro, Daegu 41566, South Korea; Shaheed Benazir Bhutto Univ SBBU, Dept Chem, Sheringal Upper Dir 18050, Khyber Pakhtunk, Pakistan | Lee, Da-hyun/NBW-9248-2025; Nayab, Saira/W-3063-2019 | 58686334300; 58686689100; 25222186500; 36490286400; 15750846000; 57194237504 | hyosunlee@knu.ac.kr;jhan@anu.ac.kr; | DALTON TRANSACTIONS | DALTON T | 1477-9226 | 1477-9234 | 52 | 45 | SCIE | CHEMISTRY, INORGANIC & NUCLEAR | 2023 | 3.5 | 28.4 | 0.64 | 2025-06-25 | 3 | 4 | COPPER(II) COMPLEX; CLEAVAGE | Copper; Crystallography, X-Ray; Deoxyribonucleases; DNA; Morpholines; Pyridines; Quinolines; Binders; Chlorine compounds; DNA; Nitrates; Pyridine; copper; copper(II) nitrate; cupric chloride; deoxyribonuclease; DNA; morpholine derivative; pyridine derivative; quinoline derivative; Copper chlorides; Cu complexes; Destabilizing agents; DNA nuclease; DNA structure; Groove binders; Morpholines; Nuclease activity; Square-pyramidal geometry; X-ray diffraction studies; chemistry; X ray crystallography; Copper compounds | English | 2023 | 2023-11-21 | 10.1039/d3dt02615a | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Optimization of Portulaca oleracea L. extract using response surface methodology and artificial neural network and characterization of bioactive compound by high-resolution mass spectroscopy | The well-known medicinal plant Portulaca oleracea L. (PO) is used as a traditional med-icine and culinary herb to treat various diseases. Fatty acids, essential oils, and flavonoids were extracted from PO seeds and leaves using ultrasonic, microwave, and supercritical fluid extraction with RSM techniques. However, investigations on the secondary metabolites and antioxidant capa-bilities of the aerial part of PO (APO) are scarce. In order to extract polyphenols and antioxidants from APO as effectively as possible, this study used heat reflux extraction (HRE), response surface methodology (RSM), and artificial neural network (ANN) modeling. It also used high-resolution mass spectrometry to identify the APO secondary metabolite. A central-composite design (CCD) was used to establish the ideal ethanol content, extraction time, and extraction temperature to extract the highest polyphenolic compounds and antioxidant activity from APO. According to RSM, the highest amount of TPC (8.23 +/- 1.06 mgGAE/g), TFC (43.12 +/- 1.15 mgCAE/g), DPPH-scavenging activity (43.01 +/- 1.25 % of inhibition) and FRAP (35.98 +/- 0.19 mM ascorbic acid equivalent) were obtained at 60.0 % ethanol, 90.2 % time, and 50 degrees C. Statistical metrics such as the coefficient of determination (R2), root-mean-square error (RMSE), absolute average deviation (AAD) , standard error of prediction (SEP) revealed the ANN's superiority. Ninety-one specialIntscript secondary metabolites, including phenolic, flavonoids, alkaloids, fatty acids, , terpenoids, were discovered using high-resolution mass spectrometry. In addition, 21 new phytoconstituents were identified for the first time in this plant. The results revealed a significant concentration of phy-toconstituents, making it an excellent contender for the pharmaceutical and food industries. (c) 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | Alshammari, Fanar; Alam, Md Badrul; Naznin, Marufa; Kim, Sunghwan; Lee, Sang-Han | Kyungpook Natl Univ, Grad Sch, Dept Food Sci & Biotechnol, Daegu 41566, South Korea; Kyungpook Natl Univ, Food & Bioind Res Inst, Inner Beauty Antiaging Ctr, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Chem, Daegu 41566, South Korea; Mass Spectrometry Converging Res Ctr, Daegu 41566, South Korea; Green Nano Mat Res Ctr, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Food Sci & Biotechnol, Daegu 41566, South Korea | Kim, Sunghwan/HKN-9812-2023; Alam, Md Badrul/AAK-7176-2021; Lee, Seung Eun/ABG-1607-2021 | 57191860948; 38662278200; 57195955389; 57203772967; 57221453703 | sang@knu.ac.kr; | ARABIAN JOURNAL OF CHEMISTRY | ARAB J CHEM | 1878-5352 | 1878-5379 | 16 | 2 | SCIE | CHEMISTRY, MULTIDISCIPLINARY | 2023 | 5.3 | 28.4 | 1.03 | 2025-06-25 | 9 | 11 | Antioxidant; Artificial neural network; Portulaca oleracea; Response surface methodol-ogy; Secondary metabolites | PHOENIX-DACTYLIFERA L.; IDENTIFICATION; DERIVATIVES; PREDICTION; PLATFORM; PROFILE; ACIDS; AJWA; OIL; RSM | Antioxidant; Artificial neural network; Portulaca oleracea; Response surface methodology; Secondary metabolites | Antennas; Antioxidants; Ascorbic acid; Biomolecules; Effluent treatment; Essential oils; Ethanol; Fatty acids; Flavonoids; Mass spectrometry; Mean square error; Medicine; Metabolites; Plant extracts; Supercritical fluid extraction; Supercritical fluids; Surface properties; Aerial parts; Bioactive compounds; Flavonoid; High resolution mass spectrometry; Neural characterization; Optimisations; Phytoconstituents; Portulaca oleracea; Response-surface methodology; Secondary metabolites; Neural networks | English | 2023 | 2023-02 | 10.1016/j.arabjc.2022.104425 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy | Purpose This post-marketing surveillance (PMS) study was conducted to monitor the usage of axitinib (Inlyta) in clinical practice of Korean patients with advanced renal cell carcinoma (RCC) with disease progression during or after a prior systemic therapy in real world.Materials and Methods In this multicenter, observational study, patients indicated for oral axitinib 5 mg twice daily as second-line therapy for advanced RCC were followed up under routine clinical practices, and their safety and effectiveness outcomes were col-lected.Results Between 2012 and 2021, 125 patients were enrolled, and data from 111 patients were analyzed. Median age was 65 years (range, 30 to 84 years), 81% was male, and 110 (99%) had clear cell RCC. The median daily dose of axitinib was 10 mg (range, 4.36 to 15.95 mg) with a median administration period of 5.6 months (range, 15 to 750 days). Eighty-three percentage of patients experienced any grade of adverse events, 71% of which were related to study treatment, including diarrhea (36%), hypertension (21%), stomatitis (17%), decreased appetite (14%), palmar-plantar erythrodysesthesia syndrome (12%), and asthenia (11%). Most adverse events were generally well tolerated and manageable, with 13% of grade >= 3. Axitinib dose reduction was required in 20% of the adverse events and discontinuation in 8%. Median progression-free survival was 12.4 months (95% confidence interval [CI], 9.6 to 18.9). Objective responses were observed in 30% of patients (95% CI, 21 to 39) with 4% of complete response and 26% of partial response.Conclusion No new safety signal was found in the present PMS study of Korean RCC patients. Axitinib showed consistent outcomes in terms of effectiveness and safety confirming that the drug is a valid option for second-line therapy in patients with advanced RCC in a real-world setting. | Shin, Sang Joon; Lee, Jae Lyun; Kwon, Tae Gyun; Shim, Byoung Young; Chung, Ho Seok; Kim, Sang-Hee; Park, Se Hoon | Yonsei Univ, Dept Internal Med, Div Med Oncol, Coll Med, Seoul, South Korea; Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Urol, Daegu, South Korea; Catholic Univ Korea, St Vincents Hosp, Coll Med, Dept Med Oncol, Suwon, South Korea; Chonnam Natl Univ, Dept Urol, Med Sch, Gwangju, South Korea; Pfizer Pharmaceut Korea Ltd, Oncol Med Affair, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, 81 Irwon ru, Seoul 06351, South Korea | Lee, Jae Lyun/AGI-4843-2022 | 57967744400; 58760078200; 15073765400; 8086955700; 56680492000; 57210566009; 25960261300 | hematoma@skku.edu; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 2 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 0 | 2025-06-25 | 1 | 0 | Carcinoma; Renal cell; Axitinib; Postmarketing product surveillance | SORAFENIB | Axitinib; Carcinoma; Postmarketing product surveillance; Renal cell | Aged; Axitinib; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Male; Republic of Korea; Treatment Outcome; axitinib; axitinib; indazole derivative; acute cholecystitis; adult; aged; anemia; Article; asthenia; brain infarction; cellulitis; chronic obstructive lung disease; clinical practice; confidence interval; decreased appetite; diarrhea; drug dose increase; drug dose reduction; drug efficacy; drug safety; drug withdrawal; dysphonia; elevated blood pressure; female; fever; hand foot syndrome; home; hospitalization; human; hyperkalemia; hypertension; incidence; Kaplan Meier method; lung embolism; major clinical study; male; malignant neoplasm; multivariate logistic regression analysis; observational study; postmarketing surveillance; progression free survival; proteinuria; pruritus; pulmonary artery thrombosis; renal cell carcinoma; stomatitis; survival analysis; systemic therapy; treatment duration; clinical trial; kidney tumor; multicenter study; pathology; renal cell carcinoma; South Korea; treatment outcome | English | 2023 | 2023-04 | 10.4143/crt.2022.883 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer | Purpose Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation-posi-tive non-small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we report on the use of osimertinib in patients with EGFR T790M mutation-positive non-small cell lung cancer who had previously received EGFR tyrosine kinase inhibitor (TKI) treatment in Korea.Materials and Methods Patients with confirmed EGFR T790M after disease progression of prior EGFR-TKI were enrolled and admin-istered osimertinib 80 mg daily. The primary effectiveness outcome was progression-free survival, with time-to-treatment discontinu-ation, treatment and adverse effects leading to treatment discontinuation, and overall survival being the secondary endpoints.Results A total of 558 individuals were enrolled, and 55.2% had investigator-assessed responses. The median progression-free survival was 14.2 months (95% confidence interval [CI], 13.0 to 16.4), and the median time-to-treatment discontinuation was 15.0 months (95% CI, 14.1 to 15.9). The median overall survival was 36.7 months (95% CI, 30.9 to not reached). The benefit with osimer-tinib was consistent regardless of the age, sex, smoking history, and primary EGFR mutation subtype. However, hepatic metastases at the time of diagnosis, the presence of plasma EGFR T790M, and the shorter duration of prior EGFR-TKI treatment were poor pre-dictors of osimertinib treatment. Ten patients (1.8%), including three with pneumonitis, had to discontinue osimertinib due to severe adverse effects.Conclusion Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation-positive in Korean patients with no new safety signals. | Lee, Jang Ho; Kim, Eun Young; Park, Cheol-Kyu; Lee, Shin Yup; Lee, Min Ki; Yoon, Seong-Hoon; Lee, Jeong Eun; Lee, Sang Hoon; Kim, Seung Joon; Lee, Sung Yong; Lim, Jun Hyeok; Jang, Tae -Won; Jang, Seung Hun; Lee, Kye Young; Lee, Seung Hyeun; Yang, Sei Hoon; Park, Dong Won; Park, Chan Kwon; Kang, Hye Seon; Yeo, Chang Dong; Choi, Chang-Min; Lee, Jae Cheol | Univ Ulsan, Asan Med Ctr, Dept Internal Med, Div Pulmonol & Crit Care Med,Coll Med, Seoul, South Korea; Yonsei Univ, Dept Internal Med, Div Pulm & Crit Care Med, Coll Med, Seoul, South Korea; Chonnam Natl Univ, Hwasun Hosp, Dept Internal Med, Lung & Esophageal Canc Clin,Med Sch, Hwasun, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Pusan Natl Univ Hosp, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med, Busan, South Korea; Pusan Natl Univ, Dept Pulmonol & Crit Care Med, Dept Internal Med, Yangsan Hosp, Yangsan, South Korea; Chungnam Natl Univ, Dept Internal Med, Div Pulmonol, Daejeon, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Div Pulmonol,Dept Internal Med, Seoul, South Korea; Korea Univ Guro Hosp, Dept Internal Med cine, Div Pulm Allergy & Crit Care Med, Seoul, South Korea; Inha Univ, Inha Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med,Coll Med, Incheon, South Korea; Kosin Univ, Coll Med, Gospel Hosp, Dept Pulmonol, Busan, South Korea; Hallym Univ, Dept Med, Div Pulm Allergy & Crit Care Med, Sacred Heart Hosp, Anyang, South Korea; Konkuk Univ, Dept Pulm Med, Sch Med, Seoul, South Korea; Kyung Hee Univ, Dept Internal Med, Div Pulm & Crit Care Med, Sch Med, Seoul, South Korea; Wonkwang Univ, Dept Internal Med, Sch Med, Iksan, South Korea; Hanyang Univ, Hanyang Univ Hosp, Dept Internal Med, Div Pulmonol Allergy & Crit Care Med,Coll Med, Seoul, South Korea; Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Div Pulm Allergy & Crit Care Med,Dept Internal Med, Seoul, South Korea; Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Allergy & Crit Care Med, Bucheon, South Korea; Catholic Univ Korea, Eunpyeong St Marys Hosp, Coll Med, Dept Internal Med,Div Pulm Allergy & Crit Care Med, Seoul, South Korea; Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea | Lee, Jeong Eun/R-8689-2019; Lee, Jeong Won/AAC-4169-2022; Kim, Eun Young/JCE-3602-2023; Lim, Jun Hyeok/ABA-5277-2021; Kim, Jung Oh/JDC-5061-2023; Lee, Joo Yong/ADE-2110-2022; PARK, DONG WON/V-7939-2017; Lee, Yo Han/IUN-3410-2023; Lee, Jae/AAA-2678-2021; Lee, Sang-Hoon/ABH-6210-2020; Park, Cheol-Kyu/AAT-9872-2021 | 57204642922; 57361264500; 57205721111; 49863712700; 16433227400; 55479240500; 57209104622; 57207065392; 57225930594; 56734650000; 57214084476; 7102426031; 7402219050; 8720534800; 57208400366; 7406950928; 55746540800; 14623269200; 55536025100; 55233857000; 14024046800; 24825051600 | jclee@amc.seoul.kr; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 1 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 1.36 | 2025-06-25 | 9 | 9 | Osimertinib; EGFR T790M; Non-small cell lung cancer; Real-world efficacy | CHEMOTHERAPY | EGFR T790M; Non–small cell lung cancer; Osimertinib; Real-world efficacy | Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Republic of Korea; afatinib; epidermal growth factor receptor; erlotinib; gefitinib; osimertinib; antineoplastic agent; epidermal growth factor receptor; osimertinib; protein kinase inhibitor; acute kidney failure; adult; age; aged; anorexia; Article; blood toxicity; cancer chemotherapy; cancer patient; cancer prognosis; cancer survival; clinical effectiveness; clinical trial (topic); cohort analysis; color vision defect; diagnosis time; diarrhea; disease exacerbation; drug dose increase; drug dose reduction; drug efficacy; drug safety; drug withdrawal; ECOG Performance Status; edema; female; gene mutation; human; liver metastasis; liver toxicity; major clinical study; male; median survival time; middle aged; nausea and vomiting; non small cell lung cancer; outcome assessment; overall response rate; overall survival; pneumonia; progression free survival; pruritus; rash; response evaluation criteria in solid tumors; retrospective study; second-line treatment; sex; smoking; South Korea; South Korean; survival analysis; survival rate; third-line treatment; time to treatment; treatment duration; treatment response; weakness; genetics; lung tumor; mutation; pathology | English | 2023 | 2023-01 | 10.4143/crt.2022.381 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Recent Trends of Medical Expenses Associated with Radiation Therapy in Korea Based on HIRA Big Data | Purpose We aimed to determine the trends in the use of radiotherapy (RT) and the expenses associated with it in South Korea. Materials and Methods The statistical data of the claims and reimbursement records provided on the Health and Insurance Review and Assessment Service website were utilized. This included information such as the number of patients, fractions, medical expenses according to treatment codes, in/outpatient, sex, age, and regions of hospitals. We analyzed data from 2016 to 2020. Results With a growing RT infrastructure and an increase in the number of radiation oncologists, the expenses for RT were 605.5 million USD in 2020, which had increased 1.5 times from 394.7 million USD in 2016. This growth was mainly because of the increased usage of advanced RT techniques. Furthermore, the proportion of intensity-modulated radiation therapy (IMRT) expenses in the total expenses increased by 1.6 times from 48.8% in 2016 to 76.9% in 2020. Advanced techniques were used more commonly in older individuals or children. However, the proportion of IMRT expenses increased mostly in young women. Additionally, geographical differences in RT use and expense were observed, although the gap in the IMRT fractions decreased among the regions. Conclusion Recent medical expenses associated with RT in Korea have increased in tandem with technological advances and changes in demographics. | Lee, Jeong Eun; Yang, Kyungmi; Ahn, Yong Chan; Park, Won; Huh, Seung Jae | Kyungpook Natl Univ, Sch Med, Dept Radiat Oncol, Daegu, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiat Oncol, Sch Med, Seoul, South Korea; Healthcare Review & Assessment Comm, Hlth Insurance Review & Assessment Serv, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiat Oncol, Sch Med, 81 Irwon Ro, Seoul, South Korea | 57206732333; 57193521957; 55666330600; 55663053400; 7101832922 | kyungmi.yang@samsung.com;sjhuh5201@gmail.com; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 3 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 0.61 | 2025-06-25 | 4 | 4 | Health care costs; Intensity-modulated; Population dynamics; Radiotherapy | RADIOTHERAPY; INFRASTRUCTURE; ONCOLOGY; PATTERNS | Health care costs; Intensity-modulated; Population dynamics; Radiotherapy; Radiotherapy | Aged; Big Data; Cell Cycle Proteins; Child; Female; Histone Chaperones; Hospitals; Humans; Radiation Oncology; Radiotherapy, Intensity-Modulated; Republic of Korea; Transcription Factors; cell cycle protein; chaperone; HIRA protein, human; transcription factor; article; big data; child; controlled study; demographics; female; health care cost; human; intensity modulated radiation therapy; male; outpatient; population dynamics; radiation oncologist; radiotherapy; reimbursement; South Korea; trend study; aged; big data; hospital; intensity modulated radiation therapy; radiation oncology; South Korea | English | 2023 | 2023-07 | 10.4143/crt.2022.389 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | Correction | Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group (vol 54, pg 1, 2022) | Yoon, Shinkyo; Kim, Miso; Hong, Yong Sang; Kim, Han Sang; Kim, Seung Tae; Kim, Jihun; Yun, Hongseok; Yoo, Changhoon; Ahn, Hee Kyung; Kim, Hyo Song; Lee, In Hee; Kim, In-Ho; Park, Inkeun; Jeong, Jae Ho; Cheon, Jaekyung; Kim, Jin Won; Yun, Jina; Lim, Sun Min; Cha, Yongjun; Jang, Se Jin; Zang, Dae Young; Kim, Tae Won; Kang, Jin Hyoung; Kim, Jee Hyun | Univ Ulsan, Asan Med Ctr, Dept Oncol, Coll Med, Seoul, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea; Yonsei Univ, Yonsei Canc Ctr, Div Med Oncol, Coll Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; Univ Ulsan, Asan Med Ctr, Dept Pathol, Coll Med, Seoul, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Genom Med, Coll Med, Seoul, South Korea; Gachon Univ, Dept Internal Med, Div Med Oncol, Gil Med Ctr, Incheon, South Korea; Kyungpook Natl Univ, Dept Oncol Hematol, Chilgok Hosp, Daegu, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Med Oncol, Seoul, South Korea; CHA Univ, CHA Bundang Med Ctr, Dept Med Oncol, Sch Med, Seongnam, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Div Hematol Med Oncol,Coll Med, Seongnam, South Korea; Soonchunhyang Univ, Dept Internal Med, Div Med Oncol, Bucheon Hosp, Bucheon, South Korea; Natl Canc Ctr Res Inst & Hosp, Ctr Colorectal Canc, Goyang, South Korea; Hallym Univ, Med Ctr, Dept Internal Med, Anyang, South Korea | KIM, SEONG/E-4164-2012; Kim, Jee/J-5441-2012; Kim, Jin Il/JWP-3629-2024; Kim, Hanjun/AAJ-7528-2021; Kim, Tae Won/GRX-7323-2022; Kang, Jin Hyoung/KYQ-2256-2024; Lee, Kee-Joon/AAA-4090-2022 | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 3 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 1 | English | 2023 | 2023-07 | 10.4143/crt.2021.1115.e | 바로가기 | 바로가기 | 바로가기 | |||||||||||||
| ○ | ○ | Article | Suggestions for Escaping the Dark Ages for Pediatric Diffuse Intrinsic Pontine Glioma Treated with Radiotherapy: Analysis of Prognostic Factors from the National Multicenter Study | Purpose This multicenter retrospective study aimed to investigate clinical, radiologic, and treatment-related factors affecting survival in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) treated with radiotherapy.Materials and Methods Patients aged = 2 years) was 16.7%, and median OS was 43.6 months. Age (< 10 years), poor performance status, treatment before 2010, and post-radiotherapy necrosis were independently associated with poor OS in multivariate analysis. In patients with increased post-radiotherapy necrosis, the median OS estimates were 13.3 months and 11.4 months with and without bevacizumab, respectively (p=0.138).Conclusion Therapeutic strategy for DIPG has remained unchanged over time, and the associated prognosis remains poor. Our findings suggest that appropriate efforts are needed to reduce the occurrence of post-radiotherapy necrosis. Further well-designed clinical trials are recommended to improve the poor prognosis observed in DIPG patients.Key words Diffuse intrinsic pontine glioma, Radiotherapy, Prognosis | Kim, Hyun Ju; Lee, Joo Ho; Kim, Youngkyong; Lim, Do Hoon; Park, Shin-Hyung; Do Ahn, Seung; Kim, In Ah; Im, Jung Ho; Chung, Jae Wook; Kim, Joo-Young; Kim, Il Han; Yoon, Hong In; Suh, Chang-Ok | Gachon Univ, Dept Radiat Oncol, Gil Hosp, Incheon, South Korea; Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Radiat Oncol, Coll Med, Seoul, South Korea; Kyung Hee Univ, Med Ctr, Dept Radiat Oncol, Sch Med, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiat Oncol, Sch Med, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Radiat Oncol, Daegu, South Korea; Univ Ulsan, Asan Med Ctr, Dept Radiat Oncol, Coll Med, Seoul, South Korea; Seoul Natl Univ, Dept Radiat Oncol, Bundang Hosp, Seongnam, South Korea; CHA Univ, CHA Bundang Med Ctr, Dept Radiat Oncol, Sch Med, 59 Yatap Ro, Seongnam 13496, South Korea; Chonnam Natl Univ, Dept Radiat Oncol, Med Sch, Gwangju, South Korea; Natl Canc Ctr, Proton Therapy Ctr, Goyang, South Korea; Yonsei Univ, Yonsei Canc Ctr, Dept Radiat Oncol, Coll Med, 50 Yonsei Ro, Seoul 03722, South Korea | Park, Shinhyung/LNQ-6428-2024; Kim, In/J-5426-2012; Lee, Joo/AAS-2614-2021 | 57191717925; 57203144684; 56900171600; 7401816010; 57203275843; 8414834000; 35210493700; 56096038400; 57220613582; 57207436986; 57811938100; 57964782300; 7102970921 | YHI0225@yuhs.ac;suhchangok@cha.ac.kr; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 1 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 1.51 | 2025-06-25 | 7 | 10 | Diffuse intrinsic pontine glioma; Radiotherapy; Prognosis | BRAIN-STEM GLIOMA; GRADE GLIOMAS; CHILDREN; CHILDHOOD | Diffuse intrinsic pontine glioma; Prognosis; Radiotherapy | Brain Stem Neoplasms; Child; Diffuse Intrinsic Pontine Glioma; Glioma; Humans; Prognosis; Retrospective Studies; bevacizumab; carmustine; etoposide; nimustine; temozolomide; thalidomide; vincristine; Article; astrocytoma; cancer diagnosis; cancer patient; cancer prognosis; cancer radiotherapy; cancer survival; child; diffuse astrocytoma; diffuse midline glioma; female; follow up; glioblastoma; glioma; histopathology; human; Korea; long term survival; major clinical study; male; multicenter study; necrosis; nuclear magnetic resonance imaging; pontine glioma; retrospective study; survival rate; task performance; treatment response; brain stem tumor; clinical trial; glioma; pathology; pontine glioma; prognosis | English | 2023 | 2023-01 | 10.4143/crt.2021.1514 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Three-dimensional ternary NixCuyZnz(CO3)(OH)2 electrodes for supercapacitors: electrochemical properties and applications | Transition metal-based binary and ternary compound arrays were directly grown on a porous Ni foam substrate using a facile one-step hydrothermal method. Transition metals are considered ideal electrode materials for faradaic capacitors because they exhibit a wide range of oxidation states enabling effective redox charge transfer. Furthermore, compounds in which two or more transition metals react can help increase the number of active sites for charge-discharge reactions and provide more valence changes for improved charge transfer. In this work, we fabricated ternary electrodes with Ni, Cu, and Zn ions, exhibiting a larger surface area and higher entropy than those made with binary compounds. The NixCuyZnz-based ternary electrode had a shorter diffusion path for the electrolyte ions owing to its larger surface area. Ternary compounds can increase the entropy of the electrode because of the reaction between atoms of different sizes, bringing about a synergistic effect for high characteristic electrochemical values. The optimized NixCuyZnz(CO3)(OH)(2) compound showed a maximum specific capacity of 344 mA h g(-1) at a current density of 3 A g(-1), which was remarkably higher than that of the binary electrode, and a cycling stability of 84.9% after 5000 cycles. An asymmetric supercapacitor produced with this compound as the positive electrode and graphene as the negative electrode exhibited a high energy density of 36.2 W h kg(-1) at a power density of 103.1 W kg(-1) and a current density of 2 A g(-1). The asymmetric supercapacitor fabricated using the NixCuyZnz(CO3)(OH)(2) compound as the positive electrode exhibited excellent electrical properties when used in an illuminated LED device. | Lee, Dong Hyun; Baek, Juyoung; Kim, Dong Hwan; Roh, Jong Wook; Kim, Jeongmin; Lee, Damin | DGIST, Div Nanotechnol, 333 Techno Jungang-daero, Daegu 42988, South Korea; Kyungpook Natl Univ, Reg Leading Res Ctr Smart Energy Syst, Daegu 41566, South Korea | 58389757300; 57188711669; 57195540717; 25638796100; 57203325094; 57194601076 | jkim@dgist.ac.kr;damin91@knu.ac.kr; | DALTON TRANSACTIONS | DALTON T | 1477-9226 | 1477-9234 | 52 | 11 | SCIE | CHEMISTRY, INORGANIC & NUCLEAR | 2023 | 3.5 | 28.4 | 1.6 | 2025-06-25 | 10 | 10 | NANOWIRE ARRAYS; NICKEL FOAM; THIN-FILMS; PERFORMANCE; GRAPHENE; CAPACITANCE; NANOSHEET; HYDROXIDE; GROWTH; CARBON | Charge transfer; Electric discharges; Electrochemical electrodes; Electrolytes; Entropy; Supercapacitor; Asymmetric supercapacitor; Binary compounds; Electrochemical applications; Foam substrates; Hydrothermal methods; Large surface area; Ni foam; Porous Ni; Positive electrodes; Ternary compounds; Transition metals | English | 2023 | 2023-03-14 | 10.1039/d3dt00143a | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer: Stage-Matched Analysis of a Large Multicenter National Cohort | Purpose Outcome analysis of urachal cancer (UraC) is limited due to the scarcity of cases and different staging methods compared to urothelial bladder cancer (UroBC). We attempted to assess survival outcomes of UraC and compare to UroBC after stage-matched analyses. Materials and Methods Total 203 UraC patients from a multicenter database and 373 UroBC patients in single institution from 2000 to 2018 were enrolled (median follow-up, 32 months). Sheldon stage conversion to corresponding TNM staging for UraC was con-ducted for head-to-head comparison to UroBC. Perioperative clinical variables and pathological results were recorded. Stage-matched analyses for survival by stage were conducted. Results UraC patients were younger (mean age, 54 vs. 67 years; p = pT3a tumors (78.8% vs. 41.8%). While 5-year recurrence-free survival, cancer-specific survival (CSS) and overall survival were comparable between two groups (63.4%, 67%, and 62.1% in UraC and 61.5%, 75.9%, and 67.8% in UroBC, respectively), generally favorable prognosis for UraC in lower stages (pT1-2) but unfavorable outcomes in higher stages (pT4) compared to UroBC was observed, although only 5-year CSS in >= pT4 showed statistical significance (p=0.028). Body mass index (hazard ratio [HR], 0.929), diabetes mellitus (HR, 1.921), pathologic T category (HR, 3.846), and lymphovascular invasion (HR, 1.993) were predictors of CSS for all patients. Conclusion Despite differing histology, UraC has comparable prognosis to UroBC with relatively favorable outcome in low stages but worse prognosis in higher stages. The presented system may be useful for future grading and risk stratification of UraC. | Song, Sang Hun; Lee, Jaewon; Ko, Young Hwii; Kim, Jong Wook; Jung, Seung Il; Kang, Seok Ho; Park, Jinsung; Seo, Ho Kyung; Kim, Hyung Joon; Jeong, Byong Chang; Kim, Tae-Hwan; Choi, Se Young; Nam, Jong Kil; Ku, Ja Yoon; Joo, Kwan Joong; Jang, Won Sik; Yoon, Young Eun; Yun, Seok Joong; Hong, Sung-Hoo; Oh, Jong Jin | Seoul Natl Univ, Coll Med, Dept Urol, Bundang Hosp, 82 Gumi Ro, Seongnam 13620, South Korea; Seoul Natl Univ, Dept Urol, Coll Med, Seoul, South Korea; Yeungnam Univ Hosp, Dept Urol, Daegu, South Korea; Korea Univ, Dept Urol, Coll Med, Seoul, South Korea; Chonnam Natl Univ, Dept Urol, Med Sch, Gwangju, South Korea; Korea Univ, Dept Urol, Sch Med, Seoul, South Korea; Eulji Univ, Eulji Univ Hosp, Dept Urol, Sch Med, Daejeon, South Korea; Natl Canc Ctr, Dept Urol, Ctr Urol, Goyang, South Korea; Konyang Univ, Myunggok Med Res Inst, Dept Urol, Coll Med, Daejeon, South Korea; Sungkyunkwan Univ, Dept Urol, Samsung Med Ctr, Sch Med, Seoul, South Korea; Kyungpook Natl Univ, Dept Urol, Coll Med, Daegu, South Korea; Chung Ang Univ, Chung Ang Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea; Pusan Natl Univ, Dept Urol, Yangsan Hosp, Yangsan, South Korea; Dongnam Inst Radiol & Med Sci, Dept Urol, Busan, South Korea; Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Urol, Sch Med, Seoul, South Korea; Yonsei Univ, Urol Sci Inst, Severance Hosp, Dept Urol,Coll Med, Seoul, South Korea; Hanyang Univ Hosp, Dept Urol, Seoul, South Korea; Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Dept Urol, Coll Med, Cheongju, South Korea; Seoul St Marys Hosp, Dept Urol, Seoul, South Korea | ; Kim, Jong Wook/HTP-6808-2023; Yoon, Young/ABG-4983-2020; Ko, Young Hwii/GRX-0718-2022; Choi, Se Young/AEB-2770-2022; Kim, Siwon/KHX-9078-2024; Kim, Hyung Joon/F-6497-2013 | 57208028472; 58658712300; 25723368800; 57192647677; 7403677192; 7405684686; 56900085500; 8418841600; 57202103629; 7102237943; 57797823600; 57209856147; 8653467500; 55373044600; 8363552700; 56646805300; 58825663400; 16302421300; 37030299600; 24468588100 | bebsuzzang@naver.com; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 4 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 0.61 | 2025-06-25 | 3 | 4 | Urinary bladder neoplasms; Urachal cancer; Cystectomy; Neoplasm staging; TNM classification; Survival analysis | ADENOCARCINOMA; SURVIVAL; OUTCOMES | Cystectomy; Neoplasm staging; Survival analysis; TNM classification; Urachal cancer; Urinary bladder neoplasms | Carcinoma, Transitional Cell; Humans; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Urachal cancer; Urinary Bladder Neoplasms; antineoplastic agent; adult; age; Article; body mass; cancer patient; cancer prognosis; cancer registry; cancer specific survival; cancer staging; cancer surgery; case control study; clinical feature; clinical outcome; cohort analysis; comparative study; controlled study; diabetes mellitus; female; follow up; histopathology; human; lymph vessel metastasis; major clinical study; male; middle aged; neoadjuvant chemotherapy; overall survival; partial cystectomy; perioperative period; predictor variable; radical cystectomy; recurrence free survival; retrospective study; survival analysis; survival prediction; survival time; transitional cell carcinoma of the bladder; tumor differentiation; urachal carcinoma; bladder tumor; cancer staging; clinical trial; multicenter study; pathology; prognosis; transitional cell carcinoma; urachal carcinoma | English | 2023 | 2023-10 | 10.4143/crt.2023.417 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors | Purpose Targeted next-generation sequencing (NGS) is widely used for simultaneously detecting clinically informative genetic alterations in a single assay. Its application in clinical settings requires the validation of NGS gene panels. In this study, we aimed to validate a targeted hybridization capture-based DNA panel (ONCOaccuPanel) using the Illumina MiSeq sequencing platform. The panel allows the simultaneous detection of single-nucleotide variants (SNVs), insertions, deletions, and copy number changes of 323 genes and fusions of 17 genes in solid tumors. Materials and Methods We used 16 formalin-fixed paraffin-embedded (FFPE) tumor samples with previously known genetic mutations and one reference material (HD827) for validation. Moreover, we sequenced an additional 117 FFPE tumor samples to demonstrate the clinical utility of this panel. Results Validation revealed a 100% positive percentage agreement and positive predictive value for the detection of SNVs, insertions, deletions, copy number changes, fusion genes, and microsatellite instability-high types. We observed high levels of reproducibility and repeatability (R2 correlation coefficients=0.96-0.98). In the limit of detection assessment, we identified all clinically relevant genes with allele frequencies > 3%. Furthermore, the clinical application of ONCOaccuPanel using 117 FFPE samples demonstrated robust detection of oncogenic alterations. Oncogenic alterations and targetable genetic alterations were detected in 98.2% and 27.4% cases, respectively. Conclusion ONCOaccuPanel demonstrated high analytical sensitivity, reproducibility, and repeatability and is feasible for the detection of clinically relevant mutations in clinical settings. | Kim, Moonsik; Lee, Changseon; Hong, Juyeon; Kim, Juhee; Jeong, Ji Yun; Park, Nora Jee-Young; Kim, Ji-Eun; Park, Ji Young | Kyungpook Natl Univ, Kyungpook Natl Univ Chilgok Hosp, Sch Med, Dept Pathol, Daegu, South Korea; NGeneBio Inc, R&D Ctr, Bioinformat Team, Seoul, South Korea; NGeneBio Inc, R&D Ctr, Diagnost Dev Team, Seoul, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Chilgok Hosp, Sch Med, Dept Pathol, 807 Hoguk Ro, Daegu 41404, South Korea | 57195918515; 58145725000; 58145526400; 58183364100; 57205472984; 57226185359; 58183418400; 57210160197 | jyparkmd@knu.ac.kr; | CANCER RESEARCH AND TREATMENT | CANCER RES TREAT | 1598-2998 | 2005-9256 | 55 | 2 | SCIE | ONCOLOGY | 2023 | 4.1 | 28.4 | 1.36 | 2025-06-25 | 9 | 10 | High-throughput nucleotide sequencing; DNA mutational analysis; Genetic testing; Validation; Neoplasms | FOR-MOLECULAR-PATHOLOGY; NONPOLYPOSIS COLORECTAL-CANCER; LYNCH-SYNDROME; LABORATORY STANDARDS; ENDOMETRIAL CANCER; GUIDELINES; ONCOLOGY | DNA mutational analysis; Genetic testing; High-throughput nucleotide sequencing; Neoplasms; Validation | Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Mutation; Neoplasms; Reproducibility of Results; DNA; DNA mismatch repair protein MSH2; mismatch repair protein PMS2; MutL protein homolog 1; protein MSH6; Article; bioinformatics; cancer of unknown primary site; clinical article; controlled study; copy number variation; diagnostic accuracy; diagnostic test accuracy study; DNA hybridization; dna mutational analysis; DNA probe; endometrium cancer; feasibility study; female; fusion gene; gene frequency; head and neck cancer; high throughput sequencing; human; human tissue; immunohistochemistry; indel mutation; limit of detection; lung cancer; male; measurement repeatability; microsatellite instability; ovary cancer; polymerase chain reaction; predictive value; reproducibility; sensitivity and specificity; single nucleotide polymorphism; skin cancer; solid malignant neoplasm; thyroid cancer; validation study; genetics; high throughput sequencing; mutation; neoplasm; pathology | English | 2023 | 2023-04 | 10.4143/crt.2022.891 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Hemodynamic performance evaluation of neonatal ECMO double lumen cannula using fluid-structure interaction | Extra corporeal membrane oxygenation (ECMO) is an artificial oxygenation facility, employed in situations of cardio-pulmonary failure. Some diseases i.e., acute respiratory distress syndrome, pulmonary hypertension, corona virus disease (COVID-19) etc. affect oxygenation performance of the lungs thus requiring the need of artificial oxygenation. Critical care teams used ECMO technique during the COVID-19 pandemic to support the heart and lungs of COVID-19 patients who had an acute respiratory or cardiac failure. Double Lumen Cannula (DLC) is one of the most critical components of ECMO as it resides inside the patient and, connects patient with external oxygenation circuit. DLC facilitates delivery and drainage of blood from the patient's body. DLC is characterized by delicate balance of internal and external flows inside a limited space of the right atrium (RA). An optimal performance of the DLC necessitates structural stability under biological and hemodynamic loads, a fact that has been overlooked by previously published studies. In the past, many researchers experimentally and computationally investigated the hemodynamic performance of DLC by employing Eulerian approach, which evaluate instantaneous blood damage without considering blood shear exposure history (qualitative assessment only). The present study is an attempt to address the aforementioned limitations of the previous studies by employing Lagrangian (quantitative assessment) and incorporating the effect of fluid-structure interaction (FSI) to study the hemodynamic performance of neonatal DLC. The study was performed by solving three-dimensional continuity, momentum, and structural mechanics equation(s) by numerical methods for the blood flow through neonatal DLC. A two-way coupled FSI analysis was performed to analyze the effect of DLC structural deformation on its hemodynamic performance. Results show that the return lumen was the most critical section with maximum pressure drop, velocity, shear stresses, and blood damage. Recirculation and residence time of blood in the right atrium (RA) increases with increasing blood flow rates. Considering the structural deformation has led to higher blood damage inside the DLC-atrium system. Maximum Von-Mises stress was present on the side edges of the return lumen that showed direct proportionality with the blood flow rate. | Ahmad, Faiq; Cheema, Taqi Ahmad; Rehman, Khawar; Ullah, Minhaj; Jamil, Muhammad; Park, Cheol Woo | GIK Inst Engn Sci & Technol, Fac Mech Engn, Topi 23460, Pakistan; Hanyang Univ, Dept Civil & Environm Engn, Seoul 04763, South Korea; GIK Inst Engn Sci & Technol, Dept Civil Engn, Topi 23460, Pakistan; Anal Grp, Starfish Med, 455 Boleskine Rd, Victoria, BC, Canada; KoC Univ, Dept Mech Engn, Sariyar, TR-34450 Istanbul, Turkiye; Kyungpook Natl Univ, Sch Mech Engn, 80 Daehak Ro, Daegu 41566, South Korea; Kyungpook Natl Univ, Sch Mech Engn, 80 Daehak Ro, Daegu 41566, South Korea | 58127567200; 36522492600; 57220461259; 58185612100; 57211458810; 7408416474 | tacheema@giki.edu.pk;chwoopark@knu.ac.kr; | INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN BIOMEDICAL ENGINEERING | INT J NUMER METH BIO | 2040-7939 | 2040-7947 | 39 | 6 | SCIE | ENGINEERING, BIOMEDICAL;MATHEMATICAL & COMPUTATIONAL BIOLOGY;MATHEMATICS, INTERDISCIPLINARY APPLICATIONS | 2023 | 2.2 | 28.5 | 0.29 | 2025-06-25 | 2 | 2 | blood damage; double lumen cannula (DLC); extra corporeal membrane oxygenation (ECMO); fluid-structure interaction (FSI); hemodynamic performance | BLOOD DAMAGE; FLOW; OXYGENATION; DESIGN; IMPACT | blood damage; double lumen cannula (DLC); extra corporeal membrane oxygenation (ECMO); fluid–structure interaction (FSI); hemodynamic performance | Cannula; COVID-19; Extracorporeal Membrane Oxygenation; Hemodynamics; Humans; Infant, Newborn; Pandemics; Blood; Damage detection; Diseases; Numerical methods; Shear flow; Shear stress; Stability; Viruses; Blood damage; Blood-flow rates; Double lumen cannula; Extra corporeal membrane oxygenation; Fluid-structure interaction; Fluid–structure interaction; Haemodynamics; Hemodynamic performance; Performance; Structural deformation; coronavirus disease 2019; extracorporeal oxygenation; hemodynamics; human; newborn; pandemic; physiology; procedures; Hemodynamics | English | 2023 | 2023-06 | 10.1002/cnm.3706 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression | BackgroundClassically activated M1 macrophages, characterized by aberrant glycolysis and secretion of inflammatory cytokines, play pivotal roles in inflammatory diseases, including inflammatory bowel disease (IBD). Recently, sodium-glucose co-transporter 2 (SGLT2) inhibitors were shown to suppress Na+/H+ exchanger 1 (NHE1) and Na+/Ca2+ exchanger 1 (NCX1) activity, regulating downstream intracellular Ca2+ concentrations in cardiomyocytes. However, whether SGLT2 inhibitors regulate M1 macrophage polarization by downregulating NHE1 and NCX1 remains unknown.MethodsWe analyzed cellular responses to SGLT2 inhibitors using mouse bone marrow-derived macrophages and peritoneal macrophages treated with lipopolysaccharide (LPS). To induce IBD, we used a dextran sulfate sodium salt-induced colitis mouse model.ResultsWe observed that NHE1 and NCX1 were overexpressed in LPS-treated macrophages, leading to M1 macrophage polarization. Mechanistically, NHE1 and NCX1-mediated Ca2+ accumulation in the macrophage resulted in enhanced glycolysis by promoting PI3K/AKT/mTORC1 signaling. SGLT2 inhibitors suppressed both the expression levels and activities of NHE1 and NCX1, and consequently downregulated PI3K/AKT/mTORC1 signaling and glycolysis in LPS-treated macrophages. We observed inhibition of LPS-stimulated M1 polarization and cytokine production by SGLT2 inhibitors in vitro, ex vivo, and in an IBD mouse model.ConclusionsNHE1 promotes M1 macrophage polarization and SGLT2 inhibitors are a novel strategy to treat M1 macrophage-mediated inflammatory diseases, including IBD. | Kim, Ye Jin; Jin, Jonghwa; Kim, Dong-Ho; Kim, Daehoon; Lee, You Mie; Byun, Jun-Kyu; Choi, Yeon-Kyung; Park, Keun-Gyu | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, 130 Dongdeok Ro, Daegu 41944, South Korea; Kyungpook Natl Univ, Res Inst Aging & Metab, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Biomed Sci, Daegu 41566, South Korea; Kyungpook Natl Univ, Coll Pharm, Vessel Organ Interact Res Ctr VOICE, MRC, Daegu 41566, South Korea; Kyungpook Natl Univ, Pharmaceut Sci Res Inst, Coll Pharm, Daegu 41566, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Dept Internal Med, Sch Med, 807 Hoguk Ro, Daegu 41404, South Korea | Lee, Kyung-Soo/C-9016-2011 | 57207443325; 57223246243; 57986980100; 58171035100; 8230508600; 57190427423; 35335932600; 57202558343 | ykchoi@knu.ac.kr;kpark@knu.ac.kr; | INFLAMMATION RESEARCH | INFLAMM RES | 1023-3830 | 1420-908X | 72 | 10-11 | SCIE | CELL BIOLOGY;IMMUNOLOGY | 2023 | 4.8 | 28.5 | 1.1 | 2025-06-25 | 7 | 7 | SGLT2 inhibitors; Macrophage; NHE1; Glycolysis; Inflammatory bowel disease | NA+/H+ EXCHANGER; INDUCED COLITIS; ACTIVATION; PATHWAY; EMPAGLIFLOZIN; CALCIUM; MODEL; MTOR; PH | Glycolysis; Inflammatory bowel disease; Macrophage; NHE1; SGLT2 inhibitors | Animals; Disease Models, Animal; Inflammatory Bowel Diseases; Lipopolysaccharides; Macrophages; Mechanistic Target of Rapamycin Complex 1; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sodium-Glucose Transporter 2 Inhibitors; B7 antigen; CD86 antigen; complementary DNA; dapagliflozin; dextran sulfate; empagliflozin; eosin; hematoxylin; hypoxia inducible factor 1alpha; inducible nitric oxide synthase; interleukin 6; lipopolysaccharide; mammalian target of rapamycin complex 1; nitric oxide; phosphatidylinositol 3 kinase; protein kinase B; S6 kinase; small interfering RNA; sodium glucose cotransporter 1; sodium proton exchange protein 1; thioglycolic acid; trifluoperazine; tumor necrosis factor; lipopolysaccharide; mammalian target of rapamycin complex 1; phosphatidylinositol 3 kinase; protein kinase B; sodium glucose cotransporter 2 inhibitor; animal cell; animal experiment; animal model; animal tissue; Article; bone marrow derived macrophage; C57BL 6 mouse; calcium cell level; cell pH; colon tissue; controlled study; cytokine production; dextran sulfate sodium-induced colitis; down regulation; ex vivo study; extracellular acidification rate; fluorescence intensity; genetic transfection; glycolysis; histology; immunofluorescence; immunohistochemistry; lamina propria; limit of quantitation; M1 macrophage; male; mouse; mouse model; nonhuman; pathogenesis; peritoneum macrophage; polarization; protein expression; RAW 264.7 cell line; real time polymerase chain reaction; Western blotting; animal; disease model; inflammatory bowel disease; macrophage; metabolism | English | 2023 | 2023-11 | 10.1007/s00011-023-01796-y | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Letter | Incidental versus symptomatic pulmonary embolism in patients without cancer | Lee, Yong Hoon; Cha, Seung-Ick; Park, Jongmin; Lim, Jae Kwang; Lee, Won Kee; Park, Ji-Eun; Choi, Sun Ha; Seo, Hyewon; Yoo, Seung-Soo; Lee, Shin-Yup; Lee, Jaehee; Kim, Chang-Ho; Park, Jae-Yong | Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Dept Radiol, Daegu, South Korea; Kyungpook Natl Univ, Med Res Collaborat Ctr, Biostat, Daegu, South Korea; Kyungpook Natl Univ Hosp, Dept Internal Med, 130 Dongdeok-ro, Daegu 41944, South Korea | ; Lee, Jaehee/S-1697-2018; Lee, Junseong/T-4139-2017 | 57199022948; 35227126400; 57216463879; 55515341400; 22953484700; 57195437358; 57199723585; 55612130200; 56479781600; 49863712700; 13805476000; 7409873555; 58360293800 | sicha@knu.ac.kr; | VASCULAR MEDICINE | VASC MED | 1358-863X | 1477-0377 | 28 | 5 | SCIE | PERIPHERAL VASCULAR DISEASE | 2023 | 3 | 28.6 | 0 | 2025-06-25 | 0 | 0 | computed tomography (CT); incidental; prognosis; pulmonary embolism (PE) | BURDEN | computed tomography (CT); incidental; prognosis; pulmonary embolism (PE) | Humans; Incidental Findings; Neoplasms; Pulmonary Embolism; adult; adverse outcome; aged; clinical outcome; cohort analysis; computer assisted tomography; controlled study; female; heart rate; human; immobilization; in-hospital mortality; incidental pulmonary embolism; injury; lung embolism; major clinical study; male; medical record review; Note; prognosis; retrospective study; risk assessment; risk factor; South Korea; surgery; symptomatic pulmonary embolism; systolic blood pressure; tachycardia; tertiary care center; venous thromboembolism; complication; incidental finding; lung embolism; neoplasm | English | 2023 | 2023-10 | 10.1177/1358863x231171614 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: